Literature DB >> 25637939

Understanding opioid reward.

Howard L Fields1, Elyssa B Margolis2.   

Abstract

Opioids are the most potent analgesics in clinical use; however, their powerful rewarding properties can lead to addiction. The scientific challenge is to retain analgesic potency while limiting the development of tolerance, dependence, and addiction. Both rewarding and analgesic actions of opioids depend upon actions at the mu opioid (MOP) receptor. Systemic opioid reward requires MOP receptor function in the midbrain ventral tegmental area (VTA) which contains dopaminergic neurons. VTA dopaminergic neurons are implicated in various aspects of reward including reward prediction error, working memory, and incentive salience. It is now clear that subsets of VTA neurons have different pharmacological properties and participate in separate circuits. The degree to which MOP receptor agonists act on different VTA circuits depends upon the behavioral state of the animal, which can be altered by manipulations such as food deprivation or prior exposure to MOP receptor agonists.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  VTA; addiction; midbrain; morphine; mu opioid receptor

Mesh:

Substances:

Year:  2015        PMID: 25637939      PMCID: PMC4385443          DOI: 10.1016/j.tins.2015.01.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  131 in total

Review 1.  Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues.

Authors:  T M Tzschentke
Journal:  Prog Neurobiol       Date:  1998-12       Impact factor: 11.685

2.  Direct bidirectional μ-opioid control of midbrain dopamine neurons.

Authors:  Elyssa B Margolis; Gregory O Hjelmstad; Wakako Fujita; Howard L Fields
Journal:  J Neurosci       Date:  2014-10-29       Impact factor: 6.167

Review 3.  The mysterious motivational functions of mesolimbic dopamine.

Authors:  John D Salamone; Mercè Correa
Journal:  Neuron       Date:  2012-11-08       Impact factor: 17.173

4.  Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness "liking" and "wanting".

Authors:  Daniel C Castro; Kent C Berridge
Journal:  J Neurosci       Date:  2014-03-19       Impact factor: 6.167

5.  Enkephalin blocks inhibitory pathways in the vertebrate CNS.

Authors:  R A Nicoll; B E Alger; C E Jahr
Journal:  Nature       Date:  1980-09-04       Impact factor: 49.962

6.  Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain.

Authors:  M Melis; G L Gessa; M Diana
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2000-08       Impact factor: 5.067

7.  Two types of neurone in the rat ventral tegmental area and their synaptic inputs.

Authors:  S W Johnson; R A North
Journal:  J Physiol       Date:  1992-05       Impact factor: 5.182

8.  A unique population of ventral tegmental area neurons inhibits the lateral habenula to promote reward.

Authors:  Alice M Stamatakis; Joshua H Jennings; Randall L Ung; Grace A Blair; Richard J Weinberg; Rachael L Neve; Frederick Boyce; Joanna Mattis; Charu Ramakrishnan; Karl Deisseroth; Garret D Stuber
Journal:  Neuron       Date:  2013-11-20       Impact factor: 17.173

9.  Opioid modulation of ventral pallidal afferents to ventral tegmental area neurons.

Authors:  Gregory O Hjelmstad; Yanfang Xia; Elyssa B Margolis; Howard L Fields
Journal:  J Neurosci       Date:  2013-04-10       Impact factor: 6.167

10.  Single rodent mesohabenular axons release glutamate and GABA.

Authors:  David H Root; Carlos A Mejias-Aponte; Shiliang Zhang; Hui-Ling Wang; Alexander F Hoffman; Carl R Lupica; Marisela Morales
Journal:  Nat Neurosci       Date:  2014-09-21       Impact factor: 24.884

View more
  127 in total

Review 1.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  Behavioural activation system sensitivity is associated with cerebral μ-opioid receptor availability.

Authors:  Tomi Karjalainen; Lauri Tuominen; Sandra Manninen; Kari K Kalliokoski; Pirjo Nuutila; Iiro P Jääskeläinen; Riitta Hari; Mikko Sams; Lauri Nummenmaa
Journal:  Soc Cogn Affect Neurosci       Date:  2016-04-06       Impact factor: 3.436

3.  Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine.

Authors:  Lucja Kudla; Ryszard Bugno; Urszula Skupio; Lucja Wiktorowska; Wojciech Solecki; Adam Wojtas; Krystyna Golembiowska; Ferenc Zádor; Sándor Benyhe; Szymon Buda; Wioletta Makuch; Barbara Przewlocka; Andrzej J Bojarski; Ryszard Przewlocki
Journal:  Br J Pharmacol       Date:  2019-12-08       Impact factor: 8.739

4.  An active inference theory of allostasis and interoception in depression.

Authors:  Lisa Feldman Barrett; Karen S Quigley; Paul Hamilton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-10-10       Impact factor: 6.237

5.  A feedback neural circuit for calibrating aversive memory strength.

Authors:  Takaaki Ozawa; Edgar A Ycu; Ashwani Kumar; Li-Feng Yeh; Touqeer Ahmed; Jenny Koivumaa; Joshua P Johansen
Journal:  Nat Neurosci       Date:  2016-11-14       Impact factor: 24.884

6.  Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Authors:  Zhenhao Shi; An-Li Wang; Kanchana Jagannathan; Victoria P Fairchild; Charles P O'Brien; Anna Rose Childress; Daniel D Langleben
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

7.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

8.  The Development of a Macromolecular Analgesic for Arthritic Pain.

Authors:  Laura Weber; Xiaobei Wang; Rongguo Ren; Xin Wei; Gang Zhao; Junxiao Yang; Hongjiang Yuan; Huiling Pang; Hanjun Wang; Dong Wang
Journal:  Mol Pharm       Date:  2019-02-14       Impact factor: 4.939

9.  Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.

Authors:  Jun-Tao Gao; Chloe J Jordan; Guo-Hua Bi; Yi He; Hong-Ju Yang; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2018-10-03       Impact factor: 7.853

10.  Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.

Authors:  Pauline Charbogne; Olivier Gardon; Elena Martín-García; Helen L Keyworth; Aya Matsui; Anna E Mechling; Thomas Bienert; Md Taufiq Nasseef; Anne Robé; Luc Moquin; Emmanuel Darcq; Sami Ben Hamida; Patricia Robledo; Audrey Matifas; Katia Befort; Claire Gavériaux-Ruff; Laura-Adela Harsan; Dominik von Elverfeldt; Jurgen Hennig; Alain Gratton; Ian Kitchen; Alexis Bailey; Veronica A Alvarez; Rafael Maldonado; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2016-12-26       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.